Genome-wide association studies (GWAS) have identified genetic variants at 34 loci contributing to age-related macular degeneration (AMD) 1-3 . We generated transcriptional profiles of postmortem retinas from 453 controls and cases at distinct stages of AMD and integrated retinal transcriptomes, covering 13,662 protein-coding and 1,462 noncoding genes, with genotypes at more than 9 million common SNPs for expression quantitative trait loci (eQTL) analysis of a tissue not included in Genotype-Tissue Expression (GTEx) and other large datasets 4,5 . Cis-eQTL analysis identified 10,474 genes under genetic regulation, including 4,541 eQTLs detected only in the retina. Integrated analysis of AMD-GWAS with eQTLs ascertained likely target genes at six reported loci. Using transcriptome-wide association analysis (TWAS), we identified three additional genes, RLBP1, HIC1 and PARP12, after Bonferroni correction. Our studies expand the genetic landscape of AMD and establish the Eye Genotype Expression (EyeGEx) database as a resource for post-GWAS interpretation of multifactorial ocular traits.
After RNA-seq quality control (Supplementary Note), 105 MGS1, 175 MGS2, 112 MGS3, and 61 MGS4 samples were selected for further analyses. The reference-transcriptome profile was generated from MGS1 control retinas ( Fig. 1a and Supplementary Data 2) and included 67% of the protein-coding genes (13, 662 ) and 6.7% of the noncoding genes (1, 462) in Ensembl, in agreement with findings from a previous study 8 . High-abundance genes (186 genes showing ≥100 fragments per kilobase of transcript per million mapped reads (FPKM)) accounted for half of the Ensembl-annotated transcripts in our RNA-seq data and were enriched in visual perception, metabolic processes, and energy homeostasis ( Supplementary Fig. 3a and Supplementary Data 2). Overall, 34% of the retinal transcripts were of mitochondrial origin ( Fig. 1a and Supplementary Fig. 3b ), thus reflecting the high concentration of mitochondria in photoreceptors 9 , the predominant cell type in the human retina 10 .
Genome-guided transcript assembly supplemented 410 putative novel long intergenic noncoding RNAs (lincRNAs) and 2,861 proteincoding isoforms of genes expressed in the retina (Supplementary Fig. 3c and Supplementary Data 2). The putative lincRNA isoforms were not enriched in any biological pathway. In contrast, predicted gene function and classification of novel protein-coding isoforms showed enrichment in Gene Ontology (GO) biological processes involving synapse structure or activity (adjusted P value = 1.37 × 10 −2 ), sensory perception (adjusted P value = 1.64 × 10 −2 ), regulation of membrane potential (adjusted P value = 3.45 × 10 −2 ), and photoreceptor maintenance (adjusted P value = 3.45 × 10 −2 ). The multidimensional scaling plot of the retina reference transcriptome against the GTEx v7 data distinguished tissue-specific clusters consistent with the defined biological replicates, whereas tissue hierarchical clustering on the mean gene expression levels revealed a high degree of similarity between the brain and retina ( Fig. 1b , Supplementary  Fig. 3d and Supplementary Fig. 4 ). We identified 247 genes with tenfold or higher expression in the retina than in at least 42 of the 53 GTEx (v7) tissues (Supplementary Data 2).
Mapping of cis-eQTLs (as defined by SNP-gene combination within ±1 Mb of the transcriptional start site of each gene; Methods) Letters NATUrE GENETICS identified 14,565 genetic variants (eVariants) controlling expression of 10,474 genes (eGenes) at a false-discovery rate (FDR) ≤0.05; these included 8,529 known protein-coding and 1,358 noncoding genes ( Fig. 1c and Supplementary Data 3). The strength of association was contingent on the eVariant's distance from the transcriptional start site of its corresponding eGene ( Supplementary Fig. 5 ). Most of the retinal cis-eQTLs were present in at least one GTEx tissue, and more retinal eQTLs replicated with an increase in GTEx tissue sample size (Fig. 1d ). The proportion of GTEx cis-eQTLs replicated in the retina was larger for GTEx tissues with smaller sample sizes 5 ( Supplementary Fig. 5f ). Almost one-third of the retina-only eQTLs observed in our study, compared with those reported by GTEx for other tissues, were attributable to the relatively larger sample size ( Supplementary Fig. 6a,b) .
We examined the global roles of eQTLs in the genetics of AMD. Quantile-quantile plots identified cis-eQTL SNPs to be enriched for AMD associations, and more pronounced enrichment was observed in eVariants shared across several tissues 11, 12 ; this relationship remained relatively consistent across all other complex disease phenotypes examined ( Supplementary Fig. 5g ). We then integrated retina eQTL results with associations reported across loci identified by AMD GWAS ( Supplementary Table 1 ). Nine lead SNPs at the GWAS loci were significant eQTLs in the retina for 19 SNPgene associations. Similar analysis showed a comparable number of lead SNPs and eQTLs in several GTEx tissues (Supplementary Data 3). To ascertain the most likely causal variants, we applied eCAVIAR, which calculates the colocalization posterior probability to identify the variant responsible for both AMD-GWAS and retina eQTL signals, after accounting for local linkage disequilibrium (LD) patterns. At the recommended threshold of 1% colocalization posterior probability 13 , we discovered likely causal SNPs and underlying target genes at six AMD loci (Supplementary Table 1 and Fig. 2a ). The lead GWAS signal at two loci (B3GALTL and RDH5/CD63) was identified as the most likely causal SNP, whereas the likely causal variant was distinct from the lead SNP at four other loci: SLC16A8 (rs5756908), ACAD10 (rs7398705), TMEM97/VTN (rs241777), and APOE (rs157580) ( Supplementary Table 1 ).
We leveraged retinal eQTLs and the most recent GWAS data 3 to detect novel AMD-risk genes in a TWAS 14 using our retina transcriptome data. Gene expression was modeled with SNPs within a 1-Mb window by using mixed models, Least Absolute Shrinkage and Selection Operator (LASSO), and elastic net. The TWAS identified 61 transcriptome-wide-significant gene-AMD associations (FDR ≤0.05), which passed a gene expression model fit filter (R 2 > 0.01) (Supplementary Data 4). We detected 38 genes within 1 Mb of 13 AMD-GWAS loci, 28 of which passed genome-wide Bonferroni correction ( Fig. 2b ). TWAS analysis also identified 23 genes outside the GWAS loci ( Fig. 2c) ; these genes were located in 16 separate regions (±1 Mb). Three of these-RLBP1, PARP12, and HIC1-were the only significant genes in the region and remained so even after Bonferroni correction; these genes were therefore considered the strongest new candidate AMD-associated genes ( Fig. 2d ). Conditional testing of the full 61 significant (FDR ≤0.05) candidates identified 47 independent signals (α = 0.05). A permutation test (Methods) demonstrated two of the genes (MTMR10 and SH3BGR) at least 1 Mb outside of any GWAS region, and the TWAS associations were significantly informed by eQTL data after Bonferroni correction for the number of genes permuted (α = 0.05; 
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Supplementary Data 4). However, we note that the test is overly conservative in the presence of LD.
We compared the data from eQTL, eCAVIAR, and TWAS to highlight the most plausible target genes; B3GLCT and BLOC1S1 were each identified as the only target gene at two AMD loci by all three methods, whereas SH2B3, PLA2G12A, PILRB, and POLDIP2/TMEM199 were likely targets at four additional loci identified by two methods ( Table 1 and Supplementary Fig. 7) . A comparison of these findings with those reported in GTEx 5, 15 showed that the contribution of these SNPs to gene regulation varied across different tissues (Supplementary Data 3 and Supplementary Supplementary  Fig. 8a ). Thus, similarly to results for other complex diseases 16, 17 , our differential expression analysis did not detect many gene expression changes, probably because of heterogeneity caused by aging, polygenic inheritance, and environmental factors. We then examined biological pathways by gene set enrichment analysis (GSEA). 
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Immune-regulation and cholesterol-metabolism pathways, previously implicated in GWAS 3 , were upregulated in early and advanced AMD, whereas pathways associated with synapse development and function were largely and exclusively downregulated in intermediate AMD (Supplementary Data 5). We note that most of the genes within susceptibility loci for advanced AMD did not appear to be associated with intermediate AMD despite sufficient power 3 . Thus, intermediate AMD may not be a transitional stage between early and advanced AMD but a separate entity with unique and distinct genetic underpinnings that require further exploration. Furthermore, weighted genecoexpression network analysis of all samples suggested that several of the pathways implicated in AMD operate through closely connected networks in the retina ( Supplementary Fig. 8b ,c and Supplementary Data 6). GWAS have successfully identified variants at hundreds of loci that contribute to health-and disease-associated traits, thereby defining their broad genetic architecture 18, 19 . Interpretation of GWAS findings, however, remains a major challenge, because a large proportion of associated variants are not in protein-coding genomic regions, and their effects on specific phenotypes often individually appear to be small 20, 21 . eQTL analysis in disease-relevant tissues appears to be a prominent tool for biological interpretation of GWAS loci 11, 22 . Owing to the large sample size, we were able to identify 14,856 eQTLs that modulate retinal gene expression, a substantial proportion of which are not reported in GTEx v7 data. Moreover, we connected the lead GWAS signal to specific target genes at six known AMD-associated loci by at least two lines of evidence. Two of the target genes were validated by three independent methods: B3GLCT encodes a glucosyltransferase 23 , and its loss of function leads to Peters plus syndrome 24 ; BLOC1S1 encodes a subunit of a multiprotein complex associated with the biogenesis of an organelle of the endosome-lysosome system 25 , and its altered function can affect synaptic function 26 . Thus, altered expression of B3GLCT and BLOC1S1 might affect extracellular-matrix stability or signaling and the degradation of unwanted/recycled proteins, respectively, thereby contributing to AMD pathogenesis. We attribute the lack of obvious target genes at the remaining AMD-GWAS loci to multiple factors, including LD structure, variants affecting expression in trans or in other AMD-relevant tissues (such as retinal pigment epithelium and choroid), and the power of this study. Interpretation of eVariants that regulate multiple genes at a particular locus requires further biological validation.
AMD is notable among complex traits because of its high heritability and large effect sizes for individual GWAS SNPs 3 . We show that variants associated with gene expression across many tissues as eQTLs, as opposed to those with only tissue-specific associations, are enriched in AMD associations despite high tissue specificity of the disease itself (Supplementary Data 3 and Supplementary  Fig. 5g ). We hypothesize that, at least in part, such associations reflect larger, more robust effects among the shared eQTLs. Not surprisingly, the retina is the only tissue for which we detected regulation consistently across all six identified SNPs (Supplementary Data 3). In addition, 36 of the 61 retina-identified TWAS candidates were significant (FDR ≤0.05) in at least one GTEx tissue. The remaining candidates could not be analyzed because they had no expression or heritability in the GTEx tissues, or they were not replicated in any other tissue. Our results corroborate findings from recent studies 12, 27 and suggest that the best way to increase power for gene discovery through TWAS and similar approaches is to increase the diversity of tissues for greater resolution of the effects of regulatory variants. We emphasize, however, that eQTL effects detected only in a tissue without biological relevance, but not in a relevant tissue, would be difficult to interpret for disease-specific phenotypes. Although other tissues may show same eQTLs, the retinal effects of eQTLs are more likely to be directly relevant. We suggest that eQTL analyses of retinal pigment epithelium and choroid would further contribute to the understanding of genes involved in AMD pathobiology. AMDassociated genes uncovered by TWAS provide additional insights into the relevance of gene regulation to phenotypic consequences in this complex disease.
EyeGEx complements the GTEx project and provides a reference for the biological interpretation of genetic variants associated with common ocular traits, including glaucoma and diabetic retinopathy. Comparative analysis of retinal transcriptomes and eQTLs with the GTEx data should assist in exploring biological questions relating to visual function in syndromic and multifactorial traits. B3GLCT is the new gene symbol for B3GALTL. SH2B3 was identified by GWAS colocalization (eCAVIAR) and TWAS, two of the three criteria used to identify target genes in our study. Despite its high eQTL P value, SH2B3 is an excellent biological candidate for AMD because of its association with inflammation. eQTL analysis was based on 406 postmortem donor retina samples.
URLs
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Online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/ s41588-019-0351-9.
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Methods
Study subjects. Postmortem human donor eyes were procured by the Minnesota Lions Eye Bank after informed consent from the donor or next of kin was obtained, in accordance with the tenets of the Declaration of Helsinki. These studies were approved by the institutional review boards of the University of Minnesota and National Eye Institute, National Institutes of Health. Exclusion criteria for donors included a history of diabetes or glaucoma. Donors were also excluded from this study if, upon examination of donor macular images, there were clinical symptoms of diabetic retinopathy, advanced glaucoma, myopic degeneration, or the presence of atypical debris in the eyes. Donor eyes were enucleated within 4 h of death and stored in a moist chamber at 4 °C until retinal dissection was performed. Dissection and classification of donor retinas for AMD were carried out according to the four-step MGS as previously described 6, 28 . Tissue sections were flash frozen in liquid nitrogen and stored at -80 °C until further processing. Samples with ambiguous or no MGS levels were excluded from downstream analysis. Details of donor characteristics are described in the Supplementary Note.
GTEx data. RNA-seq and genotyping data from GTEx release v7 were downloaded from the Database of Genotypes and Phenotypes (dbGaP) under accession phs000424.v7.p2 and from the GTEx portal (see URLs), respectively.
RNA-seq, genotyping, and quality control. Details of RNA-seq, genotyping, and quality control are provided in the Supplementary Note.
Batch correction. Surrogate variables were identified and estimated for known batch effects as well as latent factors by using the supervised SVA (SSVA version 3.28.0/3.24.4) method [29] [30] [31] based on the following model:
~ + + gene expression MGS sex age
Negative-control genes for SSVA were selected from a reported list of 3,804 housekeeping genes that are uniformly expressed across 16 human tissues 32 . The Pearson method was used to determine correlations between all significant surrogate variables identified by SSVA and possible sources of variation, including biological and technical factors. Known batch effects were assessed with Principal Variance Component Analysis (PVCA) (version 1.23.0) before and after batch correction 33 . All surrogate variables identified by SSVA were used for batch correction. Additional details are described in the Supplementary Note.
Reference transcriptome. We generated the control human retina transcriptome profile from 105 MGS1 retinas by applying two criteria for gene expression: the first was to remove weakly expressed genes across all MGS stages (i.e., ≥1 CPM in ≥10% of all 453 samples), and the second was to describe the transcriptomic landscape in the retina with greater confidence (i.e., ≥2 CPM in ≥50% of all 105 MGS1 samples). We calculated the cumulative transcriptional output as previously defined 34 by converting CPM into FPKM values to take gene length into account. Similarities in transcriptomes between the retina and 53 GTEx tissues were observed with a gene filter of ≥1 CPM in ≥10% of all samples across all tissues, whereas a different gene filter, namely ≥1 CPM in ≥10% of samples within each tissue, was applied to identify genes whose expression was at least tenfold higher in the retina than in other tissues. Pathway enrichment analysis was performed with GO biological-process terms 35, 36 within clusterProfiler version 3.4.4 (ref. 37 ) by using a Benjamini-Hochberg-adjusted P value ≤0.05 as the significance threshold. The analysis and classification of potentially novel isoforms of known genes and unknown intergenic transcripts were performed with the Cufflinks suite, version 2.21 (refs. 38, 39 ). Further details are provided in the Supplementary Note.
Comparison of transcriptomes across retina and GTEx tissues. Raw GTEx v7
RNA-seq data were analyzed through our bioinformatics pipeline as described above for the retina. Effects due to differences in bioinformatics pipelines between our analysis and that of GTEx were compared, as described in the Supplementary Note.
cis-eQTL mapping. The analysis included 406 individuals for whom genotype and retina gene expression data were available, 17,389 genes expressed at ≥1 CPM in at least 10% of the retina samples, and 8,924,684 genotyped and imputed common variants. Cis-eQTL analysis was conducted with QTLtools version 1.0 (ref. 40 ) , with a linear model to adjust for disease status (MGS level), age, sex, population stratification (ten principal components), and batch effects (21 surrogate variables). In the first step of the analysis, the variant most associated with each gene was selected, and then permutation was used to determine the distribution of its test statistic under the null. This procedure was subsequently used to obtain the P value for each gene. These P values were adjusted for multiple testing with the q-value approach 41 at the desired type I-error level. The second step of the analysis involved the identification of all eVariants with independent effects on a given eGene (significant gene from the first stage). This step was done by using the genelevel thresholds derived from the first stage and then identifying which variants exhibited nominal P values below these thresholds, on the basis of the forwardbackward stepwise regression algorithm.
GTEx comparison. To calculate π 1 , we compared our cis-eQTL discoveries by using the following definition: π 1 = P(cis-eQTL in discovery tissue is significant in replication tissue | cis-eQTL in discovery tissue was also analyzed in the replication tissue)
Thus, for each cis-eQTL (gene-variant combination) we required that the combination be analyzed in both tissues being compared. 3 were analyzed. Those not found either were not in the reference dataset used for imputation (six variants) or did not pass our MAF threshold of <1% (five variants). Matrix eQTL version 2.1.1 (ref. 42 ) was then used to obtain the marginal associations by using the same cis criteria, which were then corrected for multiple testing only for the number of variants tested, by using the Bonferroni method with a type I error rate of 5%.
GWAS lead-variant analysis. Forty-one lead variants from AMD-GWAS
Enrichment. In general, we processed quantile-quantile plots for each GWAS dataset by removing all SNPs within ±1 Mb of the known GWAS signals and subsetting to variants with a MAF of at least 5%, after removing variants in the major histocompatibility region. The remaining variants were then grouped according to eQTL characteristics. Details can be found in the Supplementary Note.
Colocalization. Likely colocalizing variants between the eQTL and the GWAS data were identified with eCAVIAR version 2.0 (ref. 13 ) (Supplementary Note) on the basis of marginal statistics from the cis-eQTL analysis and from AMD GWAS 3 .
TWAS.
To perform the TWAS, the log-transformed, SSVA-corrected expression data from the 406 samples in our dataset that both passed RNA-seq and genotyping quality control were inverse-normal transformed (rank offset = 3/8) 42 to moderate the influence of potential outliers. Expression was then controlled for sex, age, and the ten population-structure variables determined by Eigenstrat version 7.2.1 (refs. 44, 45 ). For each gene, we took the subset of SNPs within 1 Mb of its start or end site that had GWAS statistics 3 by using VCFtools version 0.1.15 (ref. 45 ). TWAS implementation was performed according to Gusev et al. 14 , heritability was calculated with GCTA version 1.21 (ref. 46 ), and genetic control of expression was modeled with mixed models, LASSO, or elastic net (α = 0.5), depending on which of the three methods produced the highest fivefold cross-validation R 2 .
The effect sizes from these models acted as weights. Weighted z scores were summed for each gene, and this gene-trait association statistic was divided by its standard deviation while LD was accounted for between GWAS statistics. Standardized gene-level scores were tested against the standard normal distribution on both sides. The FDR was calculated to account for multiple testing across genes with calculated P values; genes that had an FDR <0.05 were considered significant. We also determined whether genes passed a 0.05 significance threshold after Bonferroni correction. Genes were then filtered according to their model expression fit; genes with a genetic model R 2 <0.01 were discarded.
We also performed a permutation test to determine the role that the eQTL data played in the associations: for genes with a TWAS P value <0.001, weights were randomly assigned to SNPs, and the gene-level z scores were recomputed for an adaptive number of iterations to generate a null distribution against which the original TWAS statistic was tested 14 . Details on the methods used for the conditional TWAS test can be found in the Supplementary Note. Differential expression. Differential expression was assessed with the limma package in R version 3.34.2 (ref. 47 ) with a significance threshold of FDR ≤0.20. MGS was treated as an ordinal variable in pairwise comparisons between controls and each AMD stage. Differential expression was performed with adjustments for sex and batch effects (22 surrogate variables), with or without age as a covariate. Age was the most significant nongenetic risk factor for AMD, and age-related gene expression changes would probably be relevant to AMD. We therefore also performed differential expression analysis without correcting for age to generate a comprehensive list of candidate genes that require further investigation to ascertain their contribution to AMD pathogenesis. Additional differential expression analyses, performed after the removal of samples with conditions such as hypertension, high cholesterol, and cardiovascular disease, were consistent across all comparisons made (data not shown).
Gene set enrichment analysis and leading-edge analysis. GSEA was performed by preranking genes by significance and the direction of fold change from differential expression analysis, and then testing for association with the GO biological-process gene set deposited in the GSEA MSigDB resource version 2.2.4 (ref. 48 ). Leading-edge analysis was performed on gene sets reaching a significance threshold of FDR ≤0.25 and absolute normalized enrichment score of ≥2.0. Significant gene sets were further classified into common functional categories by visualization of the GO structure as described in the Supplementary Note (see URLs).
Weighted gene-correlation network analysis. Weighted gene-correlation network analysis 49 was performed on all 453 samples that passed RNA-seq quality control,
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NATUrE GENETICS to group genes by expression profile, with the associated software WGCNA version 1.51. The log-transformed expression values were corrected for age, sex, and batch effects (determined by SSVA [29] [30] [31] . Adjacency was calculated with Spearman correlation, and the power by which we raised the absolute values of the correlation to obtain the adjacency matrix was k = 3. Through hypergeometric testing, at a significance threshold of 0.05 α after Bonferroni correction for multiple testing, modules were assessed for the enrichment of the following types of genes: (i) genes deemed relevant to macular-degeneration pathogenesis in the literature, (i) genes within 500 kb of the 34 AMD loci identified through GWAS 3 , and (iii) genes identified as leading edge by GSEA 48 . A list of genes relevant to AMD was obtained from a previous published study 50 and was updated through extensive PubMed searching (through December 2017) with one of several search terms (Supplementary Note). Pathway analysis was performed on each module with GO biological-process terms 35, 36 through clusterProfiler version 3.4.4 (ref. 37 ). The connections between genes in modules were visualized with Cytoscape version 3.5.1 (ref. 51 ).
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Unique biological materials Policy information about availability of materials Obtaining unique materials Post-mortem human donor eyes were procured by the Minnesota Lions Eye Bank after informed consent from the donor or next of kin and in accordance with the tenets of the Declaration of Helsinki. The unidentified retina samples were obtained for genotyping and RNA analyses. Human retina tissue is difficult to obtain. We obtained small punches of postmortem retina from controls and cases from University of Minnesota (Dr. Deb Ferrington). These samples were converted into total RNA and DNA. Almost all of the RNA has been used for obtaining the transcriptome data. Similarly, the DNA used for genotyping was relatively small and has been used for other experiments.
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